CJC-1295 With DAC – 5mg

CJC-1295 With DAC is a modified analogue of growth hormone-releasing hormone (GHRH), a signalling peptide involved in stimulating growth-hormone release from the pituitary gland.

CJC-1295 was developed to investigate substantially longer-lasting GHRH-related signalling than is possible with shorter-duration GHRH analogues. Its Drug Affinity Complex (DAC) modification enables the peptide to associate covalently with circulating albumin, extending its persistence in the bloodstream.

This makes the DAC-containing form chemically and pharmacokinetically distinct from the shorter-duration modified GHRH material often described as CJC-1295 Without DAC.

Published controlled research has examined CJC-1295 With DAC in relation to growth-hormone secretion, IGF-1 responses, peptide half-life and the pattern of GH release during prolonged GHRH-receptor stimulation.

Together, these characteristics make CJC-1295 With DAC relevant to research examining sustained GH-axis signalling, albumin-associated peptide design and extended-duration peptide pharmacokinetics.

Pronoia supplies CJC-1295 With DAC in a 5mg lyophilised research format with batch traceability and supporting documentation available for the supplied material.

Product: CJC-1295 With DAC

Strength: 5mg

Material class: Modified GHRH analogue

Parent framework: hGRF / GHRH-derived peptide

Peptide length: 30 residues

Modification: Drug Affinity Complex (DAC)

DAC feature: Maleimidopropionyl modification on the added C-terminal lysine

Research characteristic: Albumin-binding extended-duration peptide design

Research focus: Prolonged GH / IGF-1 signalling, pharmacokinetics and GH pulsatility

Form: Lyophilised solid

Pronoia minimum purity standard: ≥99%

Batch traceability: Maintained

SKU: PB-CJCDAC-5

Pronoia maintains a structured quality, testing and traceability process for CJC-1295 With DAC, with supporting documentation retained for the supplied research material.

• Batch-tested research material
• Pronoia minimum accepted purity standard of ≥99%
• Full batch traceability
• Batch-separated and labelled inventory
• Physical inventory routinely reconciled with digital stock records
• Temperature-controlled cold storage
• Certificate of Analysis (COA) and Safety Data Sheet (SDS) documentation available

The applicable Certificate of Analysis should be treated as the authoritative reference for the identity, purity and analytical results reported for an individual batch.

CJC-1295 With DAC has been investigated in preclinical studies and controlled human pharmacology research examining how an albumin-binding GHRH analogue changes the duration and pattern of growth-hormone-axis signalling.

The DAC modification is central to this research profile. CJC-1295 incorporates an albumin-reactive chemical group on an added C-terminal lysine. Association with circulating albumin increases peptide stability and substantially extends persistence compared with shorter-duration GHRH-related peptides.

Early development studies demonstrated prolonged circulating CJC-1295-related material and identified albumin-associated peptide following administration, providing experimental support for the mechanism behind its extended pharmacokinetic profile.

Controlled research in healthy adults subsequently examined growth hormone, IGF-1 and CJC-1295 concentrations following administration.

After a single administration, researchers reported:

• Dose-dependent increases in mean growth-hormone concentrations lasting six days or longer
• Sustained increases in mean IGF-1 concentrations for approximately nine to eleven days
• An estimated CJC-1295 half-life of approximately 5.8 to 8.1 days under the conditions studied

Research involving repeated administration also reported mean IGF-1 concentrations remaining above baseline for an extended experimental period.

A separate controlled study examined whether prolonged GHRH stimulation altered the normal pulsatile pattern of growth-hormone release.

Researchers reported that:

• Growth-hormone pulsatility remained present during prolonged CJC-1295 exposure
• The frequency and magnitude of GH secretory pulses were not significantly altered
• Baseline, or trough, GH concentrations increased substantially
• Mean overall GH secretion increased
• IGF-1 concentrations increased alongside the prolonged GH response

These findings distinguish CJC-1295 With DAC as a useful research material for studying sustained GHRH-receptor signalling while preserving the pulsatile characteristics of endogenous growth-hormone secretion.

The published human evidence consists principally of early controlled pharmacokinetic and pharmacodynamic research rather than established therapeutic use. Findings from those studies should therefore be interpreted within their specific experimental settings and do not establish clinical efficacy, safety for personal use or suitability for human or veterinary use.

CJC-1295 With DAC is supplied in lyophilised form and should be stored according to the conditions specified by Pronoia and the applicable batch documentation.

Pronoia stock is maintained in temperature-controlled cold storage and organised by identifiable batch prior to dispatch.

The material should be protected from unnecessary exposure to heat, moisture and light and handled using appropriate laboratory procedures.

Where batch-specific storage or handling information is supplied, that information should take precedence.

CJC-1295 With DAC is dispatched from Pronoia’s UK stock using tracked delivery.

Current availability and dispatch information are shown directly on the product page, with tracking supplied following dispatch.

Orders are prepared through Pronoia’s established research-product fulfilment process, with applicable delivery conditions remaining subject to Pronoia’s current delivery terms.

CJC-1295 With DAC supplied by Pronoia Bio is intended for laboratory research and experimental use only.

It is not supplied for human or veterinary use and should not be treated as a medicine or consumer healthcare product.

Pronoia does not provide dosage, treatment or administration guidance for this research material.